Shares of Bind Therapeutics, Inc. (BIND) are up 64% in early trading Thursday after the company provided clinical update for BIND-014. Bind said it achieved development milestone as part of the Pfizer (PFE) collaboration.
“We are pleased to see these phase 2 data for BIND-014 demonstrating that our Accurin technology is providing on-target anti-tumor activity with meaningful reductions in the incidence and severity of side-effects expected from conventional drugs,” said Hagop Youssoufian, M.D., chief medical officer at Bind Therapeutics.
BIND shares recently gained $3.45 to $8.60. The stock, currently trading at an unusually high volume with 4.9M shares changing hands, is down more than 34% year-over-year. In the past 52 weeks, shares of Cambridge, Massachusetts-based company have traded between a low of $5.13 and a high of $14.75.
BIND Therapeutics, Inc. closed Wednesday at $5.15. Ticker has a total market cap of $150 million.
Amicus Therapeutics, Inc. (FOLD) is surging in pre-market trading, up nearly 11% to $9.46 from Wednesday’s close of $8.54. The gains have been aided by the co.’s additional positive data on an important cardiac endpoint from its first Phase 3 study and the Phase 3 extension of the oral small molecule chaperone migalastat HCl (“migalastat”) for Fabry disease.
John F. Crowley, Chairman and CEO of Amicus Therapeutics, Inc. stated, “The effects of migalastat on Fabry patients with amenable mutations continue to be very profound. For the first time we are able to show that migalastat can lead to a reduction in LVMi in Fabry patients who are ERT-treatment naïve.”
Shares of Google Inc. (GOOG) are down $2.90 to $498.20 in pre-market trade after Stifel Nicolaus downgraded its rating to ‘Hold’ from ‘Buy’, saying it does not see significant sources of future upside for the shares.
Google Inc. is currently valued at $339.93 billion. In the past 52 weeks, shares of the search giant have traded between a low of $489.00 and a high of $604.83 with the 50-day MA and 200-day MA located at $526.70 and $558.62 levels, respectively. Additionally, shares of GOOG trade at a P/E ratio of 1.40 and have a Relative Strength Index (RSI) and MACD indicator of 33.89 and -14.32, respectively.
GOOG currently prints a one year loss of around 9%.
RBC Capital on Thursday said BlackBerry‘s (BBRY) plans for monetizing its non-smartphone assets appear to be compelling and leverage its competitive advantages. The research firm remains however, cautious on the name due to the large declines in its service revenue.
Shares are Sector Perform rated with a 12-month base case estimate of $11 per share.
On valuation measures, BlackBerry Limited shares have a PEG ratio of -1.41. Price/Sales for the same period is 1.53 while EPS is ($1.43). Currently there are 2 analysts that rate BBRY a ‘Buy’, 20 rate it a ‘Hold’. 6 analysts rate it a ‘Sell’. BBRY has a median Wall Street price target of $10.00.
In the past 52 weeks, shares of Waterloo, Canada-based company have traded between a low of $7.01 and a high of $12.54 and are now fractionally higher at $10.71. Shares are up 25.53% year-over-year and down 2.82% year-to-date.
Shares of Cyren Ltd. (CYRN) are up 13% to $2.00 in early trade Thursday after the company announced that Reliable Networks is the latest UK reseller under distributor VCW Security to offer the cloud-based CYREN WebSecurity solution.
In the past 52 weeks, shares of Herzliya, Israel-based firm have traded between a low of $1.40 and a high of $4.10. Shares are down 41.00% year-over-year ; up 2.91% year-to-date.
Risk Our Money Not Yours | Get 50% Off Any Account
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!
Leave a Reply